Related Experiment Video
Updated: Aug 10, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
Published on: January 28, 2014
Key considerations when assessing clinical utility for biomarker testing: A checklist
Tianyi Wang1, Kimberly Tsai2, Steven S Kheloussi3
1Omnicom Health Market Access, New York, NY.
Abstract:
Establishing the clinical utility of biomarker tests is a critical component of benefit design. However, payers and laboratory benefit manager organizations may differ in how they evaluate clinical utility for a given test, including how they determine whether evaluated outcomes are clinically meaningful. These differences can create challenges for providers and manufacturers when navigating coverage policies across organizations. Based on expert insights from a partnership forum hosted by AMCP on June 24-25, 2025, in Alexandria, VA, on the topic of precision medicine in oncology, we developed a checklist of considerations to align payers and laboratory benefit managers around a shared, actionable approach to evaluating the clinical utility of biomarker tests and the types of evidence used to demonstrate it. The checklist begins with confirmation that analytical and clinical validity have been established before assessing clinical utility. Tests should then be categorized based on their intended use and whether they provide actionable information that informs clinical decision-making and improves patient health outcomes. Assessment of clinical utility includes consideration of the relevance, strength, and consistency of the supporting evidence base. After clinical utility is established, economic and operational considerations may also be evaluated. This checklist is intended to support a more transparent and structured approach to evaluating clinical utility in coverage decision-making.
More Related Videos
07:35Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
Published on: October 11, 2018
07:40Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis
Published on: March 20, 2021
Related Concept Videos
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Sensitivity, Specificity, and Predicted Value
Sensitivity is the...
Receiver Operating Characteristic Plot
Clinical Trials
There are four phases in a clinical trial. A phase one...
Automated Microbial Diagnostics
Preclinical Development: Overview